Merck Sharp & Dohme Corp. - Recruiting 18 years to 70 years. - A Non-randomized, Single-panel, Open-label Trial to Study the Safety, Tolerability and Pharmacodynamics of MK-8892 Acute Dosing in Subjects With Moderate to Severe Pulmonary Arterial Hypertension.
Boehringer Ingelheim - Recruiting 20 years or older. - An Eight-week Randomised Double-blind Study to Compare the Efficacy and Safety of Telmisartan 80 mg and Amlodipine 5 mg and Hydrochlorothiazide 12.5 mg vs. Telmisartan 80 mg and Amlodipine 5 mg in Patients With Hypertension Who Fail to Respond Adequately to Treatment With Telmisartan 80 mg and Amlodipine 5 mg.
Boehringer Ingelheim - Recruiting 19 years or older. - A Regulatory Requirement Post-Marketing Surveillance Study to Monitor the Safety and Efficacy of Twynsta (Telmisartan + Amlodipine SPC, q.d.) in Korean Hypertensive Patients Requiring Combination Therapy.
Questcor Pharmaceuticals, Inc. - Recruiting 18 years or older. - A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Adaptive Design Pilot Safety and Efficacy Study of H.P. Acthar Gel (Acthar) in Patients With Diabetic Nephropathy and Proteinuria..
Control group who are advised for proper life style modification by the physician such as regular exercise and healthy diet without active intervention.; Treatment group 1(Dietary intervention); Treatment group 2(dietary and exercise intervention)
Takeda - Recruiting 20 years or older. - A Study to Explore the Effects of Azilsartan Compared to Telmisartan on Insulin Resistance of Patients With Essential Hypertension on Type 2 Diabetes Mellitus by HOMA-R.
University of Arizona - Recruiting 18 years to 80 years. - Comprehensive Characterization Of Right Ventricular Performance And Afterload In Patients With Pulmonary Arterial Hypertension Undergoing Initiation And Rapid Dose Escalation Of Treprostinil.
Actelion - Recruiting 18 years to 80 years. - A Multi-center, Open-label, Single-arm, Phase 3b Study of Macitentan in Patients With Pulmonary Arterial Hypertension to Psychometrically Validate the PAH-SYMPACT Instrument.
Shire Development LLC - Recruiting 18 years or older. - A Phase 2, Single-blind, Randomized, Controlled, Multi-center Study to Evaluate the Efficacy and Safety of SRM003 (Vascugelr) in the Treatment of Subjects With Vascular Injury Resulting From Arteriovenous Graft Surgery for Hemodialysis Access.
Shire Development LLC - Recruiting 18 years or older. - A Phase 2, Single-blind, Randomized, Controlled, Multi-center Study to Evaluate the Efficacy and Safety of SRM003 (Vascugelr) in Improving the Rate of Arteriovenous Fistula Maturation and Use in Subjects Undergoing Surgery for Creation of an Arteriovenous Fistula for Hemodialysis Access.
Eli Lilly and Company - Recruiting 6 Months to 17 years. - A Multiple Ascending Dose Study of Tadalafil to Assess the Pharmacokinetics and Safety in a Pediatric Population With Pulmonary Arterial Hypertension.
Hospital de Clinicas de Porto Alegre - Recruiting 18 years to 75 years. - The Hypotensive Effect of Simvastatin in Hypertensive Patients: a Placebo-controlled Randomized Clinical Trial With 24-h Ambulatory Blood Pressure Monitoring.
HanAll BioPharma Co., Ltd. - Recruiting 18 years to 80 years. - A Phase 3, Randomized, Double- Blind, Multi-center, Double Dummy, Clinical Trial Comparing HL-040XC With Single Component Therapies(Atorvastatin, Losartan) to Assess the Efficacy and Safety of HL-040XC in Patients With Essential Hypertension and Hyperlipidemia.
Novartis - Recruiting 6 years to 17 years. - A Multicenter, Open-label, 18 Month Study to Evaluate the Long-term Safety and Tolerability of Valsartan in Children 6 to 17 Years of Age With Hypertension and With or Without Chronic Kidney Disease.
Atrium Medical Corporation - Recruiting 18 years or older. - ARTISAN: iCASTT RX De Novo Stent Placement for the Treatment of Atherosclerotic Renal Artery Stenosis in Patients With Resistant Hypertension.
St. Michael's Hospital, Toronto - Recruiting 40 years to 75 years. - Efficacy and Safety of Combined Rg3-enriched Korean Red Ginseng (Panax Ginseng C.A. Meyer) and American Ginseng (Panax Quinquefolius) as Poly-therapy in the Management of Concomitant Hypertension in Type 2 Diabetes.
Pfizer - Recruiting 18 years to 65 years. - An Open Label, Non-Interventional Study Of The Safety, Tolerability, And Efficacy Of Amlodipine And Olmesartan Medoxomil (NormetecTM) In Filipino Patients With Hypertension: A Post Marketing Surveillance Study.
GlaxoSmithKline - Recruiting 18 years to 75 years. - A Randomised, Multicentre, Double-Blind, Placebo-Controlled Study Of Ambrisentan In Subjects With Inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH)..
Serodus ASA - Recruiting 55 years to 80 years. - A Randomized, Double-blind, Placebo-controlled, Cross-over, Multi-center Study Assessing the Safety, Tolerability and Efficacy of SER100 10 mg s.c. Twice Daily for 2 Days in Patients With Isolated Systolic Hypertension Insufficiently Treated With 1-3 Anti-hypertensives..
University of North Carolina, Chapel Hill - Recruiting 18 years or older. - A Mixed Methods Approach to the Development and Testing of the Measure of Drug Self-Management (MeDS), an Assessment for Use in Clinical Settings Among English and Spanish-speaking Patients With Hypertension and Diabetes..
Actelion - Recruiting 12 years to 70 years. - A Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group, Phase 3 Study to Evaluate the Effects of Macitentan on Exercise Capacity in Subjects With Eisenmenger Syndrome..
Macitentan 10 mg, oral tablet, to be taken once daily.; Matching placebo oral tablet, to be taken once daily.
INO Therapeutics - Recruiting 40 years to 80 years. - A Placebo-Controlled, Double-Blind, Parallel, Randomized, Two-Part, Clinical Dose-Confirming Study Of Pulsed, Inhaled Nitric Oxide (iNO) In Subjects With World Health Organization (WHO) Group 3 Pulmonary Hypertension (PH) Associated With Chronic Obstructive Pulmonary Disease (COPD) On Long Term Oxygen Therapy (LTOT) INHALE 1.
Novartis - Recruiting 18 years or older. - An Open-label, Multi-center Protocol to Provide QTI571 to PAH Patients Who Participated in the Extension Study (A2301E1) in Japan and Are Judged by the Investigator to Benefit From Continued QTI571 Treatment.
Janssen Scientific Affairs, LLC - Recruiting 18 years to 75 years. - A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Blood Pressure Reduction With Ambulatory Blood Pressure Monitoring (ABPM), Safety, and Tolerability of Canagliflozin in the Treatment of Subjects With Hypertension and Type 2 Diabetes Mellitus.
Aerie Pharmaceuticals - Recruiting 18 years or older. - A Double-masked, Randomized, Controlled Study Assessing the Safety and Ocular Hypotensive Efficacy of PG324 Ophthalmic Solution, 0.01% and PG324 Ophthalmic Solution, 0.02%, Compared to AR-13324 Ophthalmic Solution, 0.02% and Latanoprost Ophthalmic Solution, 0.005% in Patients With Elevated Intraocular Pressure.
Aristotle University Of Thessaloniki - Recruiting 18 years to 65 years. - Comparative Study of the Effects of Telmisartan and Nebivolol on 24-h Ambulatory Blood Pressure and Arterial Stiffness in Patients With Arterial Hypertension.
Merck Sharp & Dohme Corp. - Recruiting 18 years to 70 years. - A 28-Day Multiple-Dose Titration Study to Assess the Effects of MK-8892 on Safety, Tolerability and Pharmacokinetics in Subjects With Pulmonary Arterial Hypertension.
Novartis - Recruiting 18 years to 80 years. - A Two Part Study Including a Randomized, Double Blind, Placebo Controlled, Multiple Dose Study to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LFF269 After b.i.d Dosing in Healthy Volunteers and an Open Label, Multiple Dose Pharmacokinetics Study in Hypertension Subjects.
Handok Pharmaceuticals Co., Ltd. - Recruiting 20 years or older. - Observational Study to Investigate Resistant Hypertension Prevalence Among the Hypertensive Patients Who Have Been Treated in Korean General Hospitals.
Novartis - Recruiting 6 years to 17 years. - A Multicenter, Double-blind 52 to 104 Week Off-therapy Extension Study to Evaluate the Long Term Growth and Development of Pediatric Hypertensive Patients 6 - 17 Years of Age Previously Treated With Aliskiren in Studies CSPP100A2365 and/or CSPP100A2365E1.
Mati Therapeutics Inc. - Recruiting 18 years or older. - A Phase 2 Single-Masked, Randomized, Parallel Comparison of the Latanoprost Punctal Plug Delivery System (L-PPDS) With Timolol Maleate Ophthalmic Gel Forming Solution 0.5% in Subjects With Ocular Hypertension or Open-Angle Glaucoma.
Latanoprost Punctal Plug Delivery System (L-PPDS); Timolol Maleate GFS, 0.5%
Odense University Hospital - Recruiting 65 years to 90 years. - Detection of Subclinical Atrial Fibrillation in High Risk Patients (> 65 Years, Hypertension, Diabetes Mellitus) Using Implantable Loop Recorder.
Eli Lilly and Company - Recruiting 6 Months to 18 years. - A Double-Blind Efficacy and Safety Study of the Phosphodiesterase Type 5 Inhibitor Tadalafil in Pediatric Patients With Pulmonary Arterial Hypertension.
Pfizer - Recruiting 1 year to 17 years. - A Phase 3, Multi-Center, Open-Label Study To Investigate Safety, Efficacy, And Tolerability Of Sildenafil Citrate In Pediatric Patients With Pulmonary Arterial Hypertension.
Lung Rx - Recruiting 18 years to 80 years. - A Multicenter, Double-blind, Randomized, Placebo-controlled, Phase 3 Study to Assess the Efficacy and Safety of Oral BPS-314d-MR added-on to Treprostinil, Inhaled (Tyvasor) in Subjects With Pulmonary Arterial Hypertension.
National Institutes of Health Clinical Center (CC) - Recruiting 21 years to 82 years. - The NIH Exercise Therapy for Advanced Lung Disease Trials: Response and Adaptation to Aerobic Exercise in Patients With Pulmonary Hypertension: Initial Studies for Establishing Guidelines.
Alcon Research - Recruiting 18 years or older. - Prospective, Randomized, Multi-Center Study to Evaluate the Efficacy and Tolerability of DuoTravr in Patients Previously Uncontrolled on a Beta-blocker.
INO Therapeutics - Recruiting N/A to 80 years. - Examination of Safety and Effectiveness of IK-3001 (Nitric Oxide for Inhalation) in Japanese Subjects With Pulmonary Hypertension Associated With Cardiac Surgery - Multi-Center, Open-Label, Clinical Study.
University of Sao Paulo General Hospital - Recruiting 2 Months or older. - Combined Clinical and Surgical Approaches to Congenital Heart Disease Associated With Pulmonary Arterial Hypertension (PAH-CHD).
Boehringer Ingelheim Pharmaceuticals - Recruiting 18 years or older. - Treatment Adherence to JNC 7(Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, 7th Report) Guidelines in Cardiovascular (CV)-Risk Patients Across the Middle East - the Impact of Ramadan Fasting on Achieving Treatment Goals in Daily Practice.
Sensimed AG - Recruiting 18 years or older. - A Single-center, Open Label, Prospective Study Assessing the 24-hour IOP Patterns Using SENSIMED Triggerfishr in Ocular Hypertensive Patients Newly Converted to Glaucomatous Disease Versus Stable Ocular Hypertensive Patients.
Kona Medical Inc. - Recruiting 18 years or older. - A Feasibility Study: An Evaluation of Renal Denervation Using Externally Focused Therapeutic Ultrasound With External Targeting and Tracking on Patients With Refractory Hypertension.
Genkyotex Innovation SAS - Recruiting 18 years to 80 years. - A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Study Evaluating the Safety and Efficacy of Oral GKT137831 in Patients With Type 2 Diabetes and Albuminuria.
PhaseBio Pharmaceuticals Inc. - Recruiting 18 years to 80 years. - Phase 1, Randomized, Double-Blind, Placebo-Controlled Exploratory Study That Will Assess the Safety, Tolerability, Pharmacokinetics and Hemodynamic Response to a Single 30 Minute Intravenous Infusion of VasomeraT (PB1046) in Adult Subjects With Stage 1 or 2 Essential Hypertension.
Placebo Single IV (Intravenous) Infusion; Experimental: Single IV Infusion Vasomera (PB1046)
Yuhan Corporation - Recruiting 19 years or older. - A Double-blind, Randomized, Multi-center Phase III Clinical Trial to Investigate the Safety and Efficacy Between YH16410 Versus Rosuvastatin and Telmisartan Monotherapies in Patients With Hypertension and Hyperlipidemia.
Novartis - Recruiting 60 years or older. - A Randomized, Double-blind 52-week Study to Evaluate the Safety and Efficacy of an LCZ696 Regimen Compared to an Olmesartan Regimen on Arterial Stiffness Through Assessment of Central Blood Pressure in Elderly Patients With Hypertension.
Alcon Research - Recruiting 18 years or older. - Prospective, Randomized, Single-Center Study to Evaluate 24-hour Intraocular Pressure Control With Brinzolamide 1% /Brimonidine 0.2% Fixed Dose Combination Therapy.
KGK Synergize Inc. - Recruiting 30 years to 75 years. - A Randomized, Double-blind, Placebo Controlled, Parallel Study for the Assessment of Anti-hypertensive Effect and Safety of Marealis RPC (Refined Peptide Concentrate), in Healthy Subjects With Mild or Moderate Hypertension.
University of Chicago - Recruiting 18 years or older. - Noninvasive Cardiac Output Measurements in Patients With Pulmonary Hypertension Undergoing Right Heart Catheterization With Acute Vasodilator Testing.
National Institute of Allergy and Infectious Diseases (NIAID) - Recruiting 18 years to 75 years. - A Randomized, Double-Blind, Placebo-Controlled, Phase II Multicenter Trial of a Monoclonal Antibody to CD20 (Rituximab) for the Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH).
Samsung Medical Center - Recruiting N/A or older. - Safety and Efficacy of Therapeutic Induced Hypertension in Patients With Acute Non-cardioembolic Ischemic Stroke: A Multicenter, Randomized, Open Label, Prospective, Phase 3 Study.
Assuta Hospital Systems - Recruiting 14 years to 65 years. - A Prospective Trial for Laparoscopic Adjustable Gastric Banding in Morbidly Obese Patients: Report on Weight Loss, Metabolic Changes and Quality of Life.
The First Hospital of Nanjing Medical University - Recruiting 18 years to 75 years. - Safety and Effectiveness Study of Percutaneous Catheter-based Renal Sympathetic Denervation in Patients With Drug-resistant Hypertension and Symptomatic Atrial Fibrillation.
The First Hospital of Nanjing Medical University - Recruiting 18 years to 75 years. - Safety and Effectiveness Study of Percutaneous Catheter-based Sympathetic Denervation of the Renal Arteries in Patients With Hypertension and Paroxysmal Atrial Fibrillation.
National Cancer Center, Korea - Recruiting 20 years to 80 years. - Effect of Gastrectomy and Anastomosis on Chronic Metabolic Disease Such as Diabetes and Hypertension in Early Gastric Cancer Patients.
University of Athens - Recruiting 20 years to 90 years. - EVALUATION OF BLOOD PRESSURE MEASUREMENTS OUTSIDE OFFICE: COMPARISON OF DIAGNOSIS BASED ON EITHER AMBULATORY OR HOME BLOOD PRESSURE MEASUREMENTS.
Kyoto University, Graduate School of Medicine - Recruiting 20 years or older. - Intensive Blood Pressure and LDL Lowering for Better Survival and Cardiovascular Outcome in Diabetic Patients With Coronary Artery Disease: Randomized Controlled Trial.
Dong-A Pharmaceutical Co., Ltd. - Recruiting 18 years or older. - A Placebo-controlled, Double-blind, Phase II Clinical Study to Evaluate the Efficacy and Safety of Udenafil in Patient With Pulmonary Arterial Hypertension(PAH).
University of Heidelberg - Recruiting 18 years to 80 years. - Influence of Respiratory and Exercise Therapy on Oxygen Uptake, Quality of Life in Patients With Severe Associated Pulmonary Arterial Hypertension (APAH) as Part of a Congenital Heart Defect With / Without Eisenmenger's Syndrome.
Baker IDI Heart and Diabetes Institute - Recruiting 18 years to 30 years. - The Effect of Moxonidine and Regression of Early Target Organ Damage in Young Subjects With Abdominal Obesity and Hypertension: a Randomised, Double Blind, Active Comparator Clinical Trial.
West Penn Allegheny Health System - Recruiting N/A or older. - Pharmacogenomics in Pulmonary Arterial Hypertension: A Multi-Center International Study to Determine Whether in PAH Patients Clinical Associations Exist Between the Efficacy and Toxicity of Endothelin Receptor Antagonists and Several Gene Polymorphisms in Several Key Disease-Specific and Therapy Specific Genes.
Seoul National University Hospital - Recruiting 20 years or older. - Effect of Ginseol Kg1 on Blood Pressure Lowering in Prehypertensive or Stage I Hypertensive Patients: Multicenter, Randomized, Placebo-controlled, Double-blind Study.
Hospital de Clinicas de Porto Alegre - Recruiting 30 years to 70 years. - Antihypertensive Effect of Continuous Positive Airway Pressure (CPAP) in Resistant Hypertensive Patients With Sleep Apnea: Randomized Clinical Trial.
Universidad de Antioquia - Recruiting 18 years to 65 years. - Controlled Clinical Trial of the Effect of Cocoa Consumption in Lowering Blood Pressure and in the Modulation of Endothelial Inflammation in Hypertensive Patients Assigned to an Entity Health Promoting..
Delivery and return of chocolate; Determination of blood pressure; Anthropometric Measurements; Food Anamnesis; Samples: serological tests and culture of mononuclear cells; Analysis of cytokine production
University of Michigan - Recruiting 50 years or older. - Effects of the Dietary Approaches to Stop Hypertension(DASH) Sodium-restricted Diet on Ventriculovascular Function in Heart Failure With Preserved Systolic Function.
University Medicine Greifswald - Recruiting 18 years or older. - Randomized, Prospective Investigation on the Effects of Immunoadsorption on Pulmonary Vascular Resistance in Patients With Pulmonary Hypertension.
Ziekenhuis Netwerk Antwerpen (ZNA) - Recruiting 18 years or older. - The Influence of Furosemide on Fluid Balance and Intra-abdominal Pressure in Mechanically Ventilated Critically Ill Patients With Secondary Intra-abdominal Hypertension.
St. Michael's Hospital, Toronto - Recruiting 18 years or older. - A Phase II, Double Blind Randomized Controlled Trial to Determine the Safety and Efficacy of 12.5mg of Oral Sildenafil (Viagra) Compared to Placebo to Decrease Pulmonary Hypertension in Cardiac Patients After Cardiopulmonary Bypass.
University of Pavia - Recruiting 18 years to 65 years. - Randomized, Controlled, Parallel Arm, PROBE Study to Evaluate Different Effects of Imidapril and Candesartan on Fibrinolysis and Insulin-Sensitivity in Patients With Mild to Moderate Hypertension.
Jeil Pharmaceutical Co., Ltd. - Recruiting 18 years to 75 years. - A 8-Week, Randomized, Double-Blind, Parallel Designed, Phase II Multi-Center Clinical Trial to Evaluate the Antihypertensive Efficacy and the Safety of OJP-2028 Tablets in Patients With the Uncomplicated Essential Hypertension.
Tokyo University - Recruiting 40 years to 80 years. - ONgoing Evaluation of Depressor Effect And Safety of Combination Therapy With Telmisartan and Low-Dose Hydrochlorothiazide in Patients With Hypertension Uncontrolled on Amlodipine Treatment.